Stockscreener 앱 받기
0.80
5.50%
0.0123
전일 마감가:
$0.7877
열려 있는:
$0.78
하루 거래량:
17,436
Relative Volume:
0.01
시가총액:
$3.01M
수익:
-
순이익/손실:
$-16.08M
주가수익비율:
-0.362
EPS:
-2.21
순현금흐름:
$-11.54M
1주 성능:
-7.67%
1개월 성능:
-22.34%
6개월 성능:
-58.45%
1년 성능:
-91.69%
1일 변동 폭
$0.78
$0.845
1주일 범위
$0.61
$0.97
52주 변동 폭
$0.61
$12.37
Bio Path Holdings Inc Stock (BPTH) Company Profile
명칭
Bio Path Holdings Inc
전화
(832) 742-1357
주소
4710 BELLAIRE BOULEVARD, BELLAIRE, TX
BPTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| BPTH | 0.831 | 3.01M | 0 | -16.08M | -11.54M | -2.21 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.61 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.08 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 개시 | ROTH Capital | Buy |
| 2017-11-13 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-04-18 | 개시 | Rodman & Renshaw | Buy |
| 2014-06-02 | 재개 | Maxim Group | Buy |
| 2014-05-09 | 개시 | Maxim Group | Buy |
모두보기
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Bio-Path (BPTH) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research
All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy - Yahoo Finance
Bio-Path Holdings Expands DNAbilize® Technology Applications - MSN
Bio-Path stock plunges to 52-week low, hits $0.79 By Investing.com - Investing.com Canada
Bio-Path stock plunges to 52-week low, hits $0.79 - Investing.com
Biotricity, Inc. (NASDAQ:BTCY) Q2 2025 Earnings Call Transcript - Insider Monkey
BIO-key International Reports Financial Results for Third Quarter 2024 - Defense World
First National Corporation (NASDAQ:FXNC) Declares Quarterly Cash Dividend of $0.155 per Share - Defense World
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Empire Petroleum Corporation Report Q3 2024 Financial and Operating Results - Defense World
Bio-Path Holdings Reports Third Quarter 2024 Financial Results and Expansion into Obesity Program - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2024 Earnings Call Transcript - Insider Monkey
Bio-Path: Q3 Earnings Snapshot - New Haven Register
Earnings call: Bio-Path Holdings reports Q3 2024 financials, pipeline updates - Investing.com Canada
Bio-Path Holdings Reports Third Quarter 2024 Financial Results - citybiz
Bio-Path Holdings Expands to Obesity Market, Reports $2.1M Q3 Loss, Raises $4M | BPTH Stock News - StockTitan
Bio-Path Holdings Inc (BPTH) Quarterly 10-Q Report - Quartz
Some Numbers at Parker Drilling that Make Your Stock Look Good - AOL
Bio Path Holdings Inc expected to post a loss of $1.02 a shareEarnings Preview - XM
Bio-Path (BPTH) Scheduled to Post Quarterly Earnings on Friday - Defense World
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024 - StockTitan
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma - The Manila Times
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
BPTH stock touches 52-week low at $0.84 amid sharp annual decline - Investing.com UK
T-cell Malignancies Clinical Trial Pipeline Insights Featuring 70+ Companies | DelveInsight - The Malaysian Reserve
Antisense Oligonucleotide Therapeutics Market Poised for Significant Growth, Projected to Reach $64.64 Bill... - WhaTech
RNA Interference Therapy Competitive Landscape Report 2024 (Updated) - openPR
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic
siRNA Therapeutics Market Set for Explosive Growth, Projected to Reach $48.46 Billion by 2031 - WhaTech
80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港
siRNA Therapeutics Market Set for Explosive Growth, Expected to Hit $48.46 Billion by 2031 As Revealed In N... - WhaTech
Thyroid Cancer Drug Market to Exhibit a Remarkable CAGR of 17.2% - openPR
Chronic Myeloid Leukemia (CML) Treatment Market Report Analysis, Research Studies |Novartis AG, Bristol-Myers Squibb, Te – IndiaPolitics.com - IndiaPolitics.com
Antisense Oligonucleotide (ASO) Therapeutics Market Size, Share, and Future Growth Analysis (2024-2032) - News in Assen
Antisense and RNAi Therapeutics Market Growth, Share, and Industry Forecast (2024-2032) - News in Assen
Wells Fargo & Company (WFC-N) QuotePress Release - The Globe and Mail
New World Solutions (CSE: NEWS) (OTC: REGRF) Appoints Capital Markets Veteran Martin Tremblay to Board of Directors - Wall Street Reporter
Analytical Overview: Bio-Path Holdings Inc (BPTH)’s Ratios Tell a Financial Story - The Dwinnex
Bio-Path Holdings Raises $4M Through Private Placement - TipRanks
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - The Manila Times
Why this investor is skeptical about Tesla's robotaxi event - Yahoo Finance UK
Portfolio manager sees 'no landing' for US economy - Yahoo Finance UK
Russia to raise foreign company 'exit tax' to 35% from 15%, business daily reports - Yahoo Finance UK
Bio Path Holdings Inc (BPTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):